Bambusa Therapeutics Secures $90M in Series A for Bispecific Antibodies in Immunology

BOSTON, Feb. 14, 2025 /PRNewswire/ -- Bambusa Therapeutics, Inc. (Bambusa), a biotechnology company devoted to the development of bispecific antibodies targeting immunological and inflammatory (I&I) disorders, has successfully completed an oversubscribed Series A funding round, raising approximately $90 million. This round was spearheaded by a new investor, RA Capital Management, and saw participation from several other new investors, including Janus Henderson Investors, Redmile Group, Invus, and ADAR1 Capital Management, alongside all existing investors.

The newly acquired funds will be directed towards advancing Bambusa's primary programs through Phase I clinical trials and fostering further pipeline development. As part of this financial milestone, Dr. Derek DiRocco from RA Capital Management will join Bambusa's Board of Directors.

Dr. Shanshan Xu, CEO and Founder of Bambusa Therapeutics, expressed gratitude to both new and existing investors for their confidence, emphasizing the company’s commitment to swiftly pushing its bispecific antibody pipeline into clinical stages. She highlighted that this financial backing underscores the company’s vision and execution, paving the way for developing transformative therapies aimed at addressing patient needs.

Dr. Derek DiRocco, a partner at RA Capital Management, shared enthusiasm about collaborating with Bambusa Therapeutics. He noted that the company's efforts align with the upcoming wave of therapeutics for I&I disorders, which promise to be more effective and user-friendly compared to existing treatments. Bambusa's pipeline is particularly noteworthy for its half-life extended bispecific antibodies, designed to target complementary disease-driving pathways, potentially offering a superior treatment profile for patients.

Since its inception in May 2024, Bambusa has been diligently building a comprehensive pipeline of long-acting bispecific antibodies, focusing on leveraging validated targets and biological synergy to create top-tier therapies for I&I conditions. Two of Bambusa's four programs are on schedule to enter clinical stages in the first quarter of 2025 and mid-2025, respectively.

Bambusa's leading candidate, BBT001, is a bispecific antibody with features intended to replace the current standard treatments for various dermatological conditions. Another candidate, BBT002, is described as a "platform in a molecule," with potential applications in respiratory, dermatology, and gastroenterology fields. Additional candidates, BBT003 and BB004, are also being developed with the potential to become best-in-disease therapies for inflammatory bowel diseases and rheumatological conditions.

Bambusa Therapeutics is a rapidly expanding biotechnology firm based in Boston’s Seaport district, focusing on developing innovative treatments for inflammatory and immunological conditions. The company is dedicated to advancing the field of immunology through state-of-the-art solutions.